DRIVER-CLEAN / HETEROGENEOUS EGFR/ALK/KRAS · Driver-Clean to Heterogeneous EGFR mut / ALK fusion / KRAS G12C / PD-L1 γ₁ = 14.134725141734693 · NSCLC · EGFR · ALK · KRAS G12C · PD-L1 · TMB CANCER BOARD NEURO
NSCLC · NON-SMALL CELL LUNG
Driver
EGFR mut / ALK fusion / KRAS G12C / PD-L1
Coverage
~60/100k · Most common lung cancer
Confidence
STRONG
Open Sorries
⚠ KRAS G12C resistance
⚠ MET amplification bypass
⚠ CNS metastasis penetration
HYPOTHESIS
EGFR → osimertinib. ALK → alectinib. KRAS G12C → sotorasib/adagrasib (resistance emerging).
⚠ OPEN: KRAS G12C resistance mechanisms — bypass via MET/EGFR
3Sorries
γ₁14.134725141734693
CATAN CANCER · LUNG-NSCLC